SS Innovations International (SSII) caught investors’ attention after issuing preliminary 2025 revenue guidance that points to record sales of its SSi Mantra surgical robotic systems, supported by higher installations in India and abroad.

The guidance arrived after a sharp move in the shares, with a 1 day share price return of 7.43% and a 7 day share price return of 7.43%. However, the 90 day share price return of a 39.12% decline and the 1 year total shareholder return of a 30.64% decline show that recent enthusiasm follows a tougher stretch, so momentum is only starting to rebuild from a lower base.

If this kind of healthcare robotics story has your attention, it could be a good time to scan other listed medical names through our healthcare stocks and see what stands out.

With the stock still down sharply over 90 days and 1 year, while guidance points to record 2025 revenue of about US$43.0 million, you have to ask: is there a genuine opportunity here, or is the market already pricing in future growth?

Price-to-Sales of 31.8x: Is it justified?

At a last close of US$5.93, SS Innovations International is trading on a P/S of 31.8x, which is far richer than both peers and the wider US Medical Equipment industry.

The P/S ratio compares a company’s market value to its revenue and is often used for early stage or unprofitable healthcare names where earnings are still negative. For SSII, which is currently loss making and reports a net income loss of US$11.58 million on revenue of US$36.07 million, the market is effectively putting a high price on each dollar of sales.

Relative to the US Medical Equipment industry average P/S of 3.3x and a peer group average of 7.3x, SSII’s 31.8x multiple stands out as very expensive. That gap suggests investors are attributing a premium to the company’s commercial stage robotics offering and its potential, even though there is insufficient data to assess formal revenue or earnings growth forecasts and the company remains unprofitable with earnings having declined by 31.8% per year over the past 5 years.

Result: Price-to-sales of 31.8x (OVERVALUED)

However, the story could change quickly if SSII struggles to convert hospital interest into sustained orders, or if its ongoing losses of US$11.58 million widen.

Build Your Own SS Innovations International Narrative

If you see the numbers differently or prefer to test your own assumptions, you can build a custom view in a few minutes with Do it your way.

A great starting point for your SS Innovations International research is our analysis highlighting 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If SS Innovations International is on your radar, do not stop there. Widen your watchlist with a few focused ideas that could reshape how you think about opportunities.

• Spot early stage potential by scanning these 3531 penny stocks with strong financials that pair smaller market caps with financials that still pass some basic quality checks.
• Target long term themes by checking out these 24 AI penny stocks linked to artificial intelligence, automation and data driven business models across different sectors.
• Anchor your watchlist with income candidates through these 12 dividend stocks with yields > 3% that currently offer yields above 3% alongside listed financial metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.